Iranian Journal of War and Public Health

eISSN (English): 2980-969X
eISSN (Persian): 2008-2630
pISSN (Persian): 2008-2622
JMERC
0.3
Volume 15, Issue 1 (2023)                   Iran J War Public Health 2023, 15(1): 77-82 | Back to browse issues page

Print XML PDF HTML Full-Text (HTML)


History

How to cite this article
Ghafil F, Abed al-kareem Z, Abdulredha Majeed S, Aziz N, Rasheed S. Hepatoprotective Effects of Coenzyme Q10 against Amoxiclav-induced Hepatotoxicity in the Rat Model. Iran J War Public Health 2023; 15 (1) :77-82
URL: http://ijwph.ir/article-1-1240-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Rights and permissions
1- Department of Pharmacology and Therapeutics, Faculty of Medicine, Kufa University, Kufa, Iraq
2- Department of Pharmacology and Toxicology, Collage of Pharmacy, University of Kerbala, Kerbala, Iraq
3- Department of Clinical Pharmacy, Collage of Pharmacy, University of Kerbala, Kerbala, Iraq
4- Department of Microbiology, Faculty of Medicine, University of Kufa, Kufa, Iraq
* Corresponding Author Address: Iraq-Karbala-Karbala post office. Postal Code: 1125. (noor.dh@uokerbala.edu.iq)
Abstract   (653 Views)
Aims: Amoxiclav antibiotic is a commonly prescribed medication for many medical situations. One of the side effects of amoxiclav is hepatotoxicity. Coenzyme Q10, as a potent anti-oxidant, can play a beneficial role in reducing various drug-induced hepatotoxicity. The present study aimed to evaluate the hepatoprotective effects of coenzyme Q10 against amoxiclav-induced hepatotoxicity in the rat model.
Materials & Methods: 24 male albino rats weighing 150-250g were randomly divided into four groups of six animals. The control group was given normal saline; the amoxiclav group was given 30mg/Kg/day of amoxiclav orally for 30 days; In the amoxiclav and CoQ10 group, each animal was given orally 30mg/Kg of amoxiclav, and 100mg/Kg CoQ10 orally daily for 30 days; In CoQ10 group, each rat was given 100mg/Kg CoQ10 orally daily for 30 days. At the end of the experiment, the animals were anesthetized and then scarified to assess the serum liver enzymes, as well as liver tissue samples were obtained for histopathological study.
Findings: Liver function parameters were significantly elevated in the animal group treated with amoxiclav, and hepatocellular necrosis and congestion were observed in histopathological examination. Concomitant treatment with CoQ10 and amoxiclav significantly reduced the liver enzymes and improved hepatocellular congestion and inflammation.
Conclusion: CoQ10 is a potent anti-inflammatory and anti-oxidant agent that can be used to reduce amoxiclav-induced hepatotoxicity.
 
Keywords:

References
1. Benninger MS. Amoxicillin/clavulanate potassium extended release tablets: a new antimicrobial for the treatment of acute bacterial sinusitis and community-acquired pneumonia. Expert Opin Pharmacother. 2003;4(10):1839-46. [Link] [DOI:10.1517/14656566.4.10.1839]
2. Rawat D, Nair D. Extended-spectrum β-lactamases in gram negative bacteria. J Glob Infect Dis. 2010;2(3):263-74. [Link] [DOI:10.4103/0974-777X.68531]
3. Bax R. Development of a twice daily dosing regimen of amoxicillin/clavulanate. Int J Antimicrob Agents. 2007;30 Suppl 2:S118-21. [Link] [DOI:10.1016/j.ijantimicag.2007.09.002]
4. Jacobs MR. Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections based on pharmacodynamic principles. Expert Rev Anti Infect Ther. 2005;3(3):353-60. [Link] [DOI:10.1586/14787210.3.3.353]
5. Iravani A, Richard GA. Treatment of urinary tract infections with a combination of amoxicillin and clavulanic acid. Antimicrob Agents Chemother. 1982;22(4):672-7. [Link] [DOI:10.1128/AAC.22.4.672]
6. Thong BY. Update on the management of antibiotic allergy. Allergy Asthma Immunol Res. 2010;2(2):77-86. [Link] [DOI:10.4168/aair.2010.2.2.77]
7. deLemos AS, Ghabril M, Rockey DC, Gu J, Barnhart HX, Fontana RJ, et al. Drug-Induced Liver Injury Network (DILIN). Amoxicillin-Clavulanate-induced liver injury. Dig Dis Sci. 2016;61(8):2406-16. [Link] [DOI:10.1007/s10620-016-4121-6]
8. Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950-66. [Link] [DOI:10.1038/ajg.2014.131]
9. Giordano C, Rivas J, Zervos X. An update on treatment of drug-induced liver injury. J Clin Transl Hepatol. 2014;2(2):74-9. [Link]
10. Björnsson ES. Hepatotoxicity by drugs: The most common implicated agents. Int J Mol Sci. 2016;17(2):224. [Link] [DOI:10.3390/ijms17020224]
11. Moore N, Duret S, Grolleau A, Lassalle R, Barbet V, Duong M, et al. Previous drug exposure in patients hospitalized for acute liver injury: A case-population study in the French National Healthcare Data System. Drug Saf. 2019;42(4):559-72. [Link] [DOI:10.1007/s40264-018-0752-1]
12. Donaldson PT, Daly AK, Henderson J, Graham J, Pirmohamed M, Bernal W, et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. Hepatol. 2010;53(6):1049-53. [Link] [DOI:10.1016/j.jhep.2010.05.033]
13. Choi JH, Ryu YW, Seo JH. Biotechnological production and applications of coenzyme Q10. Appl Microbiol Biotechnol. 2005;68(1):9-15. [Link] [DOI:10.1007/s00253-005-1946-x]
14. Hargreaves IP. Coenzyme Q10 as a therapy for mitochondrial disease. Int J Biochem Cell Biol. 2014;49:105-11. [Link] [DOI:10.1016/j.biocel.2014.01.020]
15. Gutierrez-Mariscal FM, Arenas-de Larriva AP, Limia-Perez L, Romero-Cabrera JL, Yubero-Serrano EM, López-Miranda J. Coenzyme Q(10) supplementation for the reduction of oxidative stress: Clinical implications in the treatment of chronic diseases. Int J Mol Sci. 2020;21(21):7870. [Link] [DOI:10.3390/ijms21217870]
16. Elshazly SM, Alsemeh AE, Ahmad EAA, Rezq S. CoQ10 exerts hepatoprotective effect in fructose-induced fatty liver model in rats. Pharmacol Rep. 2020;72(4):922-34. [Link] [DOI:10.1007/s43440-020-00075-5]
17. Allan K, Hayes K, Thomas M, Barnard K. Coenzyme Q10 supplementation in traumatic brain injury: a scoping review protocol. JBI Database System Rev Implement Rep. 2019;17(9):1901-8. [Link] [DOI:10.11124/JBISRIR-2017-003984]
18. Çolak DA, Uysal H. Protective effects of coenzyme Q10 and resveratrol on oxidative stress induced by various dioxins on transheterozigot larvae of Drosophila melanogaster. Toxicol Res. 2017;6(4):521-5. [Link] [DOI:10.1039/C7TX00027H]
19. Moon Y, Lee KH, Park JH, Geum D, Kim K. Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10. J Neurochem. 2005;93(5):1199-208. [Link] [DOI:10.1111/j.1471-4159.2005.03112.x]
20. Abed Al-Kareem Z, Aziz ND, Ali Zghair M. Hepatoprotective effect of coenzyme Q10 in rats with diclofenac toxicity. Arch Razi Inst. 2022;77(2):599-605. [Link]
21. El-Hosseiny LS, Alqurashy NN, Sheweita SA. Oxidative stress alleviation by sage essential oil in co-amoxiclav induced hepatotoxicity in rats. Int J Biomed Sci. 2016;12(2):71-8. [Link]
22. Ulla A, Mohamed MK, Sikder B, Rahman AT, Sumi FA, Hossain M, et al. Coenzyme Q10 prevents oxidative stress and fibrosis in isoprenaline induced cardiac remodeling in aged rats. BMC Pharmacol Toxicol. 2017;18(1):29 [Link] [DOI:10.1186/s40360-017-0136-7]
23. Kim SH, Naisbitt DJ. Update on advances in research on idiosyncratic drug-induced liver injury. Allergy Asthma Immunol Res. 2016;8(1):3-11 [Link] [DOI:10.4168/aair.2016.8.1.3]
24. Robins V, Kumar SL, Fausto M. The liver, gallbladder, and biliary tract. In: Kumar V, Abbas A, Aster J, editors. Robbin's basic pathology. 10th edition. Philadelphia: Elsevier; 2017. [Link]
25. Leitner JM, Graninger W, Thalhammer F. Hepatotoxicity of antibacterials: Pathomechanisms and clinical data. Infection. 2010;38(1):3-11. [Link] [DOI:10.1007/s15010-009-9179-z]
26. Jordan T, Gonzalez M, Casado M, Suarez JF, PulidoF, Guerrero E, et al. Amoxicillin clavulanic acid induced hepatotoxicity with progression to cirrhosis. Gastroenterol Hepatol. 2002;25(4):240-3. [Spanish] [Link]
27. Gane EJ, Weilert F, Orr DW, Keogh GF, Gibson M, Lockhart MM, et al. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int. 2010;30(7):1019-26. [Link] [DOI:10.1111/j.1478-3231.2010.02250.x]
28. Eftekhari A, Ahmadian E, Azami A, Johari-Ahar M, Eghbal MA. Protective effects of coenzyme Q10 nanoparticles on dichlorvos-induced hepatotoxicity and mitochondrial/lysosomal injury. Environ Toxicol. 2018;33(2):167-77. [Link] [DOI:10.1002/tox.22505]
29. Mazandaran AA, Khodarahmi P. The protective role of Coenzyme Q10 in metallothionein-3 expression in liver and kidney upon rats' exposure to lead acetate. Mol Biol Rep. 2021;48(4):3107-15. [Link] [DOI:10.1007/s11033-021-06311-2]
30. Zhang P, Chen S, Tang H, Fang W, Chen K, Chen X. CoQ10 protects against acetaminophen-induced liver injury by enhancing mitophagy. Toxicol Appl Pharmacol. 2021;410:115355. [Link] [DOI:10.1016/j.taap.2020.115355]
31. Littarru GP, Tiano L. Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol Biotechnol. 2007;37(1):31-7. [Link] [DOI:10.1007/s12033-007-0052-y]
32. Ashkani Esfahani S, Esmaeilzadeh E, Bagheri F, Emami Y, Farjam M. The effect of co-enzyme Q10 on acute liver damage in rats, a biochemical and pathological study. Hepat Mon. 2013;13(8):e13685. [Link] [DOI:10.5812/hepatmon.13685]
33. Farsi F, Mohammadshahi M, Alavinejad P, Rezazadeh A, Zarei M, Ahmadi Engali K. Functions of coenzyme Q10 supplementation on liver enzymes, markers of systemic inflammation, and adipokines in patients affected by nonalcoholic fatty liver disease: A double-blind, placebo-controlled, randomized clinical trial. J Am Coll Nutr. 2016;35(4):346-53. [Link] [DOI:10.1080/07315724.2015.1021057]

Add your comments about this article : Your username or Email:
CAPTCHA